Depression is one of the most widely misunderstood psychological conditions in the modern world. A lot of people simply assume that it’s about people feeling said. Unfortunately, it goes a lot deeper than that since it can mean a constant, crippling absence of any sensation related to happiness or satisfaction. In an effort to curtail the damage that this condition can do, a new app equipped with an artificial intelligence is being tested right now.
One of the most effective treatments for depression is talking to psychotherapists who will work with patients through their emotional distress. However, talking about depression is not easy and plenty of people often avoid it altogether. The new app called Woebot could provide an effective bridge in such situations by giving patients an avenue for a conversation with something that’s not human, Business Insider reports.
The app was created by Stanford University clinical psychologist Alison Darcy. According to her, Woebot was based on the treatment cognitive-behavioral therapy (CBT), which is intended to measure patient reactions to challenging scenarios. Darcy also notes that while Woebot can’t replace human therapists, it can still pave the way to recovery.
“What we haven’t done a good job of in [therapy] is give people an array of options — what about the people who aren’t ready to talk to another person?” Darcy said. “This is part of the idea of meeting people where they’re at.”
As to how effective the chatbot can even be, Darcy and her team published a study that showed a marked improvement in patients suffering from depression while interacting with Woebot. Naturally, more research is needed in order to make any kind of concrete conclusion with regards to using AI-powered chatbots as official psychological treatment tools.
However, this development does signal an encouraging direction in which therapists can go. The rate of suicide among teens and young adults has seen an alarming rise over recent years. This technology could pave the way to substantially reducing that.


RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment
Golden Dome Missile Defense: Anduril and Palantir Join Forces on Trump's $185B Space Shield
SK Hynix Eyes Up to $14 Billion U.S. IPO to Fund AI Chip Expansion
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan
Judge Dismisses Sam Altman Sexual Abuse Lawsuit, But Sister Can Refile
Jeff Bezos Eyes $100 Billion Fund to Transform Manufacturing With AI
Microsoft Eyes Legal Action as Amazon-OpenAI Deal Threatens Azure Exclusivity
Trump White House Unveils National AI Policy Framework for Congress
Nintendo Switch 2 Production Cut as Holiday Sales Miss Targets
Palantir's Maven AI Earns Pentagon "Program of Record" Status, Reshaping Military AI Strategy
CDC Acting Director Urges Measles Vaccination as U.S. Cases Surge in 2026
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment
Nanya Technology Shares Surge 10% After $2.5 Billion Private Placement from Sandisk and Cisco
Moderna to Pay Up to $2.25B to Settle LNP Patent Dispute Over COVID-19 Vaccine Technology 



